A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. [electronic resource]
Producer: 20180213Description: 899-907 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Benzimidazoles -- administration & dosage
- Carboplatin -- administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug-Related Side Effects and Adverse Reactions -- pathology
- Fanconi Anemia Complementation Group D2 Protein -- genetics
- Female
- Humans
- Leukemia, Biphenotypic, Acute -- drug therapy
- Leukemia, Myelomonocytic, Chronic -- drug therapy
- Male
- Middle Aged
- Myeloproliferative Disorders -- drug therapy
- Poly (ADP-Ribose) Polymerase-1 -- antagonists & inhibitors
- Topotecan -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.